Exelixis (EXEL) Shares are Down -0.36%

Exelixis (EXEL) has risen sharply, recording gains of 19.39% in the past 4 weeks. However, the stock has corrected -0.36% in the past 1 week, providing a good buying opportunity on dips. Exelixis (EXEL) : Traders are bullish on Exelixis (EXEL) as it has outperformed the S&P 500 by a wide margin of 19.64% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.29%, relative to the S&P 500.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 3.67% and the fifty day Moving Average is 20.35%. Exelixis, Inc. is up 72.87% in the last three month period. Year-to-Date the stock performance stands at 94.33%.

Exelixis (EXEL) : Average target price received by Exelixis (EXEL) is $10.67 with an expected standard deviation of $2.31. The most aggressive target on the stock is $12, whereas the most downbeat target is $8. 3 financial analysts are currently covering the stock.


Exelixis (NASDAQ:EXEL): stock turned positive on Friday. Though the stock opened at $10.94, the bulls momentum made the stock top out at $11.07 level for the day. The stock recorded a low of $10.705 and closed the trading day at $10.96, in the green by 0.46%. The total traded volume for the day was 4,638,672. The stock had closed at $10.91 in the previous days trading.

Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States. The Companys other programs include metastatic renal cell carcinoma (mRCC), a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL, a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888, a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *